本文对32例急性缺血性脑血管病人纤溶酶活性测定结果,为缺血性脑血管病急性期用纤溶酶激活药物和纤溶酶的生物代用品治疗提供了依据,并提示应用这类药物治疗宜在发病初(15～20天内)进行。预计用药后能纠正凝血与纤溶因子在发病早期的失调状态,达到较好的治疗效果。特别是对纤溶酶活性降低明显,提示预后不良的或纤溶缺陷的病人,应用纤溶酶制剂可能会取得好的效果。 In this paper, 32 cases of acute ischemic cerebrovascular disease in patients with plasminogen activity measurement results for the acute phase of ischemic cerebrovascular disease with plasminogen activator drugs and plasminogen bio-substitutes provide the basis for treatment, and prompted the use of this Class drug therapy should be early onset (15 to 20 days). It is expected to correct the coagulation and fibrinolysis factors in the early onset of disorders after treatment, to achieve better therapeutic effect. In particular, plasmin activity decreased significantly, suggesting that poor prognosis or fibrinolytic defects in patients with fibrinolytic agents may achieve good results.